Literature DB >> 6220468

Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines.

M Nakajima, T Irimura, D Di Ferrante, N Di Ferrante, G L Nicolson.   

Abstract

After transport in the blood and implantation in the microcirculation, metastatic tumor cells must invade the vascular endothelium and underlying basal lamina. Mouse B16 melanoma sublines were used to determine the relation between metastatic properties and the ability of the sublines to degrade enzymatically the sulfated glycosaminoglycans present in the extracellular matrix of cultured vascular endothelial cells. Highly invasive and metastatic B16 sublines degraded matrix glycosaminoglycans faster than did sublines of lower metastatic potential. The main products of this matrix degradation were heparan sulfate fragments. Intact B16 cells (or their cell-free homogenates) with a high potential for lung colonization degraded purified heparan sulfate from bovine lung at higher rates than did B16 cells with a poor potential for lung colonization. Analysis of the degradation fragments indicated that B16 cells have a heparan sulfate endoglycosidase. Thus the abilities of B16 melanoma cells to extravasate and successfully colonize the lung may be related to their capacities to degrade heparan sulfate in the walls of pulmonary blood vessels.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6220468     DOI: 10.1126/science.6220468

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  90 in total

1.  A rapid quantitative assay for the detection of mammalian heparanase activity.

Authors:  C Freeman; C R Parish
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

Review 2.  Cell-matrix interactions during tumor invasion.

Authors:  J R Starkey
Journal:  Cancer Metastasis Rev       Date:  1990-09       Impact factor: 9.264

3.  A structural analysis of glycosaminoglycans from lethal and nonlethal breast cancer tissues: toward a novel class of theragnostics for personalized medicine in oncology?

Authors:  Amanda Weyers; Bo Yang; Dae Sung Yoon; Jong-Hwan Park; Fuming Zhang; Kyung Bok Lee; Robert J Linhardt
Journal:  OMICS       Date:  2012-03

4.  Ultrastructure of invasion in different tissue types by Lewis lung tumour variants.

Authors:  S Paku; J Timár; K Lapis
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

5.  Absence of a relationship of size of primary colon carcinoma with metastasis and survival.

Authors:  W Miller; D Ota; G Giacco; V Guinee; T Irimura; G Nicolson; K Cleary
Journal:  Clin Exp Metastasis       Date:  1985 Jul-Sep       Impact factor: 5.150

Review 6.  Role of plasma, platelets, and endothelial cells in tumor metastasis.

Authors:  G J Gasic
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

7.  Malignant melanoma metastasis to brain: role of degradative enzymes and responses to paracrine growth factors.

Authors:  G L Nicolson; M Nakajima; J L Herrmann; D G Menter; P G Cavanaugh; J S Park; D Marchetti
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

8.  A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics.

Authors:  Uri Barash; Victoria Cohen-Kaplan; Gil Arvatz; Svetlana Gingis-Velitski; Flonia Levy-Adam; Ofer Nativ; Ronen Shemesh; Michal Ayalon-Sofer; Neta Ilan; Israel Vlodavsky
Journal:  FASEB J       Date:  2009-12-09       Impact factor: 5.191

Review 9.  Mechanisms of heparanase inhibitors in cancer therapy.

Authors:  Benjamin Heyman; Yiping Yang
Journal:  Exp Hematol       Date:  2016-08-26       Impact factor: 3.084

10.  Heparanase mRNA expression and point mutation in hepatocellular carcinoma.

Authors:  Xiao-Peng Chen; Yin-Bib Liu; Jing Rui; Shu-You Peng; Cheng-Hong Peng; Zi-Yan Zhou; Liang-Hui Shi; Hong-Wei Shen; Bin Xu
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.